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RISK FACTORS OF SEPSIS DEVELOPMENT AFTER PERCUANEOUS
NEPHROLITHOTOMY
Ian-Seng Cheong, Yeong-Chin Jou, Chang-Te Lin, Ming-Chin Cheng,
Chang-Huang Shen, Pi-Che Chen. Divisions of Urology, Department of
Surgery, Chiayi Christian Hospital, Chiayi, Taiwan
Purpose: Sepsis is a life-threatening complication after percutaneous
nephrolithotomy (PCNL). The aim of this study is to identify the possible
predisposing factor of sepsis after PCNL.
Materials and Methods: Retrospective review of all patient received PCNL
between January 2001 and December 2015 in our hospital. There were
1477 cases included and 19 (1.29%) of them developed sepsis after PCNL.
Univariate and multivariable analyses identiﬁed risk factor associated with
sepsis after PCNL.
Results: There was no difference in gender, age, body mass index and
diabetes mellitus history in developing sepsis. There also no signiﬁcant
difference was noted in the mean stone size in sepsis or non-sepsis group.
Comparing the operation time, no signiﬁcant difference was noted be-
tween two groups. In 19 patients developed sepsis, 17 of them was
admitted for renal stone (OR: 8.70; 95% CI 2.00e37.79; P¼ 0.004) and 2 of
them for staghorn stone. There was no sepsis was noted in 313 of 1477
cases for upper ureteral stone after PCNL. Furthermore, Residual stone
after PCNL was noted in 10 of 19 patients (OR: 3.36; 95% CI 1.36e8.34;
P¼ 0.009).
Conclusion: The major factors of developing post PCNL sepsis are pre-
operative renal stone and residual stone after PCNL. Early identiﬁcation of
high-risk patient after PCNL may help broad-spectrum antibiotic pre-
scription earlier in order to control sepsis progression.
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THE DISTRIBUTION OF URINARY STONE COMPONENT FROM ROUTINLY
STONE ANALYSIS IN SOUTH TAIWAN
Chan-Jung Liu, Ho-Shyan Huang, Yorng-Ming Lin. Department of Urology,
Cheng-Kung University Hospital, Tainan, Taiwan
Purpose: Analysis of urinary stones is important to provide adequate
treatment, prevention, and health educations. The purpose of this study
was to determine the type, composition, age, gender and anatomic sites of
urinary stones, and their relationships with metabolic syndromes in pa-
tients treated at NCKH during the period from 2010 to 2015.
Materials and Methods: We retrospectively reviewed patients who
received stone analysis from 2010 to 2015 in a single medical center in
South Taiwan. A total 1061 patients was enrolled. Stone specimen was
submitted by patients or collected by endoscopic surgery to NCKUH. All
stone analyses were performed at the clinical laboratory. Other than stone
analyses, serum creatinine, urine pH value, 24hr urine calcium, and 24hr
urine citrate were all collected. Based on preoperative image, stone loca-
tion and stone size were also recorded.
Results: Among all, CaOx remained the most common stone component
(53.3%), which followed by Ca3(PO4)2 (27.9%). Mean age of all patients was
58.79 year old. Brushite stone accounted for 1.8%. Patients with metabolic
stones were signiﬁcantly older than CaOx or Ca3(PO4)2 (69 v.s. 55 and 58)
(p< 0.01). The ratio of male and female was obviously high in CaOx (8.3:1)
and metabolic group (28.0:1). Infection stone was dominant in female
population (1:2.8). Urine pH was lower in CaOx and metabolic groups
(pH¼ 5.9 and 5.8). 24hr urine calcium was signiﬁcantly higher in CaOx
group (219 mg/day, p< 0.01). Pre-operative renal function was worst in
metabolic group (eGFR¼ 51.4 mL/min/1.73m2). Infection stones were
prone to recur than other stone components, which need 2.2 times of
procedure to manage. On the other hand, the stone component distribu-
tion changed within age. Older people will have more Ca3(PO4)2 and
infection stones.
Conclusion: CaOx was still the most common stone components in South
Taiwan. However, Ca3(PO4)2 accounted for more percentage in South
Taiwan than other reports before. Interesting, metabolic stones shared
higher incidence in South Taiwan, which may be explained to be related to
unique climate and diet habits. Metabolic stones had also higher incidence
in older groups.Podium-7
Laparoscopy
PD7-1:
ROBOT-ASSISTED RADICAL NEPHROURECTOMY AND BLADDER CUFF
EXCISION e A SINGLE INSTITUTE EXPERIENCE
Meng-Che Tai 1, Tzu-Chun Wei 1,2, Xial-Jen Zhong 1,2, Alex T.L.
Lin 1,2, Kuang-Kuo Chen 1,2. 1Department of Urology, Taipei Veterans
General Hospital, Taiwan; 2Department of Urology, School of Medicine and
Shu-Tien Urological Institute, National Yang-Ming University, Taipei, Taiwan
Purpose: For patient with localized upper tract urothelial carcinoma,
radical nephrourectomy and bladder cuff excision (RNU+BCE) was the
standard treatment. In recent years, robot-assisted RNU and BCE (RaR-
NU+BCE) had been another choice of surgical intervention. This article was
aimed to analyse the efﬁcacy and peri-operative outcomes regarding
RaRNU+BCE by this single institutional experience.
Materials and Methods: From March 2012 to November 2015, total 54
patients with upper tract urothelial carcinoma were treated with RaR-
BU+BCE at Taipei Veterans General Hospital. We collected demographic
data, histopathological reports, and peri-operative complications.
Results: Total 54 patients were included in our study. The mean age
was 71.9 ± 9.9 (range 48e88) and the mean body mass index was
23.5± 2.9 (range 16.4e30.8). Median operative time was 314 min.
(RaRNU:133.9 ± 41.4 mins, RaBCE: 72.9± 25.7 mins). The ﬁrst docking
time was 26.8± 7.7 mins and the second docking time was 16.5 ± 6.7
mins. Median bleeding volume was 87.7 ml. Pathological stage distri-
bution was 27.8%, 7.4%, 31.5%, 13.0%, 33.3% and 5.6% in pTa, pTis, pT1,
pT2, pT3 and pT4, respectively. Complications occurred in 7 cases (13%),
with 4 grade I and 3 grade II by Clavien-Dindo classiﬁcation.
Conclusion: Our experience showed RaRNU+BCE is an technically feasible
and safe procedure for selected patients with upper tract urothelial car-
cinoma.
PD7-2:
LAPAROENDOSCOPIC SINGLE SITE (LESS) PARTIAL NEPHRECTOMY
Ching-Chia Li 1,2,3, Hsin-Chih Yeh 1,2,3, Hsiang-Ying Lee 1,2,3, Chia-Chun
Tsai 1,2,3, Kuang-Shun Chueh 1,2,3, Nien-Ting Hou 1,2,3, Yueh-Huei
Lin 1,2,3, Hung-Lung Ke 1,2,3, Chun-Nung Huang 1,2,3, Yii-Her
Chou 1,2,3, Wen-Jeng Wu1,2,3. 1Department of Urology, Kaohsiung
Municipal Ta-Tung Hospital, Kaohsiung, Taiwan; 2Division of Urology,
Department of OO, Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan; 3Department of Medical, Faculty of Medicine, College of Medicine,
Kaohsiung Medical University, Kaohsiung, Taiwan
Purpose: Laparoscopic or robotic-assisted partial nephrectomy has gained
wider acceptance as a surgical technique in treating small renal tumors.
Laparoendoscopic single site partial (LESS) partial nephrectomy is still a
technically demanding surgery to this day. We present our technique of
LESS partial nephrectomy, one that is performed with limited warm
ischemic time.
Materials and Methods: FromMarch 2012 to March 2016, ﬁfteen patients
of Kaohsiung Medical University Hospital and Kaohsiung Municipal Ta-
Tung Hospital with localized renal parenchymal tumor (stage T1) were
included. Our procedure involves the covering of renal defect layer by layer
by FloSeal, Tisseel and a fat pad after mono-polar coagulation. Commercial
single portsdLagiport (Lagis, Taiwan) were used in our operation.
Results: Fifteen patients were included in this study. Mean patient agewas
61.3 years (range47e76). Mean tumor size was 3.0 cm (range 1.7e6.3).
Mean RENAL nephrometry score was 5.1 (range 4e7). The average oper-
ation time was 191.0 minutes (range 160e245). The average warm
ischemic time was 15.6 minutes (range 9e26). Mean estimated blood loss
was 230 ml (range 30e650). No recurrent tumor can be identiﬁed at a
mean follow-up of 19 months postoperatively.
Conclusion: Our technique has shown to reduce warm ischemic time
signiﬁcantly and provide patients with excellent functional and cosmetic
outcomes without impacting oncological results. With this technique, LESS
partial nephrectomy will be a safe and effective technique for patients with
stage T1 tumor.
